Huangzhibin

Blood cell development is a complex process governed by multi-factorial regulation. Aberrant development or dysfunction can lead to severe hematological disorders, such as leukemia, posing a significant threat to human health. However, current understanding of the genetic variations underlying hematological diseases in human populations remains limited, and effective therapeutic drugs are still lacking. Therefore, elucidating the molecular mechanisms regulating hematopoiesis and disease pathogenesis, alongside establishing and optimizing high-throughput drug screening platforms, is crucial for overcoming bottlenecks in clinical treatment. In this context, in vivo high-throughput drug screening technology based on zebrafish disease models offers distinct advantages.

My research focuses on blood cell development and the screening/development of drugs for leukemia treatment via induced differentiation therapy. Through a systematic workflow encompassing mutant screening — mechanistic analysis of development — disease model construction — drug discovery and evaluation, I have published over 30 SCI-indexed papers, which have garnered more than 300 citations, resulting in an H-index of 11.

As a first author or corresponding author, I have published original research in internationally renowned journals, including: Annals of Hematology (2025), Autophagy (2024, IF: 15), Journal of Genetics and Genomics (2024, IF: 7.1), Open Biology (2024), Animal Models and Experimental Medicine (2024), Nature Communications (2023, IF: 14), Haematologica (2021, IF: 8), Journal of Biological Chemistry (2021), Leukemia (2017, IF: 13), and Blood (2016, IF: 23).

I have secured three projects funded by the National Natural Science Foundation of China as the Principal Investigator, along with two provincial/ministerial-level grants. Additionally, I served as a key member (with funding of 950,000 RMB) on one major research and development project and participated in two National Key R&D Program projects.